Evidence map›Paper›PMID 39812950›Full record

SynthesisAnnals of nuclear medicine2025

Current insights on PSMA PET/CT in intermediate-risk prostate cancer: a literature review.

Priscilla Guglielmo, Nicolò Buffi, Angelo Porreca, Lucia Setti, Demetrio Aricò, Lorenzo Muraglia, Laura Evangelista

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. An Innovative Approach with [Diagnostics (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Priscilla GuglielmoNuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, Italy. priscilla.guglielmo@yahoo.it.ORCID http://orcid.org/0000-0001-9150-4367
Nicolò BuffiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Angelo PorrecaDepartment of Oncological Urology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Lucia SettiNuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, Italy.
Demetrio AricòDepartment of Nuclear Medicine, Humanitas Oncological Centre of Catania, 95125, Catania, Italy.
Lorenzo MuragliaNuclear Medicine Unit, Humanitas Clinical and Research Institute IRCCS, Rozzano, Italy.
Laura EvangelistaDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this systematic review was to evaluate the role of PSMA PET/CT in intermediate-risk prostate cancer (PCa) patients, to determine whether it could help improve treatment strategy and prognostic stratification. A systematic literature search up to May 2024 was conducted in the PubMed, Embase and Scopus databases. Articles with mixed risk patient populations, review articles, editorials, letters, comments, or case reports were excluded. The quality of the papers was assessed by using the CASP criteria. The literature search returned 1111 studies; however, 1105 articles were excluded, and therefore 6 full-text papers were retrieved for the final analysis. Three out of six papers focused on the utility of SUVmax in identifying high ISUP grade in patients with intermediate-risk PCa. The latest three papers discussed the controversial role of PSMA PET/CT in predicting the lymph node involvement, mainly in the case of favorable subset. PSMA PET has completely changed the management of patients with PCa; indeed its role is still undefined in patients with intermediate-risk disease. Future perspective is to investigate larger cohorts of intermediate-risk PCa patients, to fully recognize the added value offered by PSMA PET in this category of subjects.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIPositron Emission Tomography Computed TomographyProstatic NeoplasmsHumansMaleRiskAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIIntermediate riskLymph node involvementProstate cancerPSMA PETSUVmax

Identifiers

PMID39812950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.